JP2020527575A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020527575A5 JP2020527575A5 JP2020502346A JP2020502346A JP2020527575A5 JP 2020527575 A5 JP2020527575 A5 JP 2020527575A5 JP 2020502346 A JP2020502346 A JP 2020502346A JP 2020502346 A JP2020502346 A JP 2020502346A JP 2020527575 A5 JP2020527575 A5 JP 2020527575A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- pharmaceutical composition
- mixture
- composition according
- difluorobenzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 28
- 239000000203 mixture Substances 0.000 claims 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 10
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 6
- 125000006288 3,5-difluorobenzyl group Chemical group [H]C1=C(F)C([H])=C(C([H])=C1F)C([H])([H])* 0.000 claims 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 5
- 229960000913 crospovidone Drugs 0.000 claims 5
- 235000019359 magnesium stearate Nutrition 0.000 claims 5
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 5
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 4
- 239000002775 capsule Substances 0.000 claims 4
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 4
- 239000008101 lactose Substances 0.000 claims 4
- 229960001375 lactose Drugs 0.000 claims 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 4
- HAYYBYPASCDWEQ-UHFFFAOYSA-N n-[5-[(3,5-difluorophenyl)methyl]-1h-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide Chemical compound C1CN(C)CCN1C(C=C1NC2CCOCC2)=CC=C1C(=O)NC(C1=C2)=NNC1=CC=C2CC1=CC(F)=CC(F)=C1 HAYYBYPASCDWEQ-UHFFFAOYSA-N 0.000 claims 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 3
- 229960003943 hypromellose Drugs 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 238000002156 mixing Methods 0.000 claims 3
- 229940095064 tartrate Drugs 0.000 claims 3
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 2
- 229960004977 anhydrous lactose Drugs 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000000905 isomalt Substances 0.000 claims 2
- 235000010439 isomalt Nutrition 0.000 claims 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- 235000002906 tartaric acid Nutrition 0.000 claims 2
- 239000011975 tartaric acid Substances 0.000 claims 2
- -1 4-methyl-piperazine-1-yl Chemical group 0.000 claims 1
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 claims 1
- 101150111783 NTRK1 gene Proteins 0.000 claims 1
- 101150117329 NTRK3 gene Proteins 0.000 claims 1
- 101150056950 Ntrk2 gene Proteins 0.000 claims 1
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 claims 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 230000009246 food effect Effects 0.000 claims 1
- 235000021471 food effect Nutrition 0.000 claims 1
- 229940057948 magnesium stearate Drugs 0.000 claims 1
- 239000007974 sodium acetate buffer Substances 0.000 claims 1
- 239000008247 solid mixture Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762534585P | 2017-07-19 | 2017-07-19 | |
| US62/534,585 | 2017-07-19 | ||
| PCT/US2018/042756 WO2019018570A1 (en) | 2017-07-19 | 2018-07-18 | PHARMACEUTICAL COMPOSITIONS CONTAINING ENTRECTINIB |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020527575A JP2020527575A (ja) | 2020-09-10 |
| JP2020527575A5 true JP2020527575A5 (https=) | 2021-08-26 |
| JP7203083B2 JP7203083B2 (ja) | 2023-01-12 |
Family
ID=63254769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020502346A Active JP7203083B2 (ja) | 2017-07-19 | 2018-07-18 | エントレクチニブを含む薬学的組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10398693B2 (https=) |
| EP (1) | EP3654952A1 (https=) |
| JP (1) | JP7203083B2 (https=) |
| KR (1) | KR102718538B1 (https=) |
| CN (2) | CN121401264A (https=) |
| AU (1) | AU2018302170B2 (https=) |
| BR (1) | BR112020000793A2 (https=) |
| CA (1) | CA3069339A1 (https=) |
| IL (1) | IL271759B2 (https=) |
| TW (1) | TWI785074B (https=) |
| WO (1) | WO2019018570A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10231965B2 (en) | 2014-02-20 | 2019-03-19 | Ignyta, Inc. | Molecules for administration to ROS1 mutant cancer cells |
| EP3227276B1 (en) | 2014-12-02 | 2021-09-01 | Ignyta, Inc. | Combinations for the treatment of neuroblastoma |
| BR112018012255A2 (pt) | 2015-12-18 | 2018-12-04 | Ignyta Inc | método para tratar câncer |
| AU2018302170B2 (en) | 2017-07-19 | 2024-02-29 | Ignyta, Inc. | Pharmaceutical compositions comprising entrectinib |
| CN111225662B (zh) | 2017-10-17 | 2022-11-22 | 伊尼塔公司 | 药物组合物和剂型 |
| AU2020319662B2 (en) | 2019-07-31 | 2024-02-29 | F. Hoffmann-La Roche Ag | New pharmaceutical formulation |
| KR20230128086A (ko) * | 2020-12-31 | 2023-09-01 | 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 | 다중 표적 단백질 키나아제 억제제의 약학 조성물 및이의 응용 |
| WO2023230454A1 (en) * | 2022-05-24 | 2023-11-30 | Icahn School Of Medicine At Mount Sinai | Neurotrophic tyrosine receptor kinase inhibitors as therapeutics for liver disease |
| WO2026074301A1 (en) * | 2024-10-02 | 2026-04-09 | Meditop Gyógyszeripari Kft | Sustained release oral medicinal product containing tolperisone hydrochloride, its production and use |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6041489A (ja) | 1983-08-12 | 1985-03-05 | Kyowa Hakko Kogyo Co Ltd | 新規生理活性物質ｋ―２５２ |
| US5736158A (en) * | 1996-03-27 | 1998-04-07 | The Block Drug Company | Partial denture cleanser with fluoride |
| TR200000020T2 (tr) | 1997-07-11 | 2000-09-21 | Janssen Pharmaceutica N.V. | 5-HT3 ve 5-HT4 aracılı bozuklar için faydalı (+)-norsisaprit. |
| WO1999043302A1 (en) * | 1998-02-27 | 1999-09-02 | Watson Pharmaceuticals, Inc. | Stabilizing composition for pharmaceutical dosage forms |
| JP2002275068A (ja) | 2001-03-16 | 2002-09-25 | Kyowa Hakko Kogyo Co Ltd | アポトーシス誘導剤 |
| ATE343575T1 (de) | 2001-09-27 | 2006-11-15 | Smithkline Beecham Corp | Azaoxoindol derivate als trk protein kinase hemmstoffe zur behandlung von krebs und chronischem schmerz |
| WO2003051847A1 (en) | 2001-12-19 | 2003-06-26 | Smithkline Beecham P.L.C. | (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors |
| FR2836915B1 (fr) | 2002-03-11 | 2008-01-11 | Aventis Pharma Sa | Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
| AU2003251875A1 (en) | 2002-07-15 | 2004-02-02 | Combinatorx, Incorporated | Combination therapy for the treatment of neoplasms |
| BR0314098A (pt) | 2002-09-05 | 2005-07-19 | Aventis Pharma Sa | Derivados da aminoindazóis a tìtulo de medicamentos e composições farmacêuticas que os contêm |
| PL376789A1 (pl) | 2002-12-12 | 2006-01-09 | Aventis Pharma S.A. | Pochodne aminoindazoli i ich zastosowanie jako inhibitorów kinazy |
| TW200423938A (en) | 2003-02-21 | 2004-11-16 | Wyeth Corp | 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury |
| CA2517256C (en) | 2003-02-26 | 2013-04-30 | Sugen, Inc. | Aminoheteroaryl compounds as protein kinase inhibitors |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| WO2005000786A1 (en) * | 2003-05-23 | 2005-01-06 | Transform Pharmaceuticals, Inc. | Sertraline compositions |
| PT2213661E (pt) | 2003-09-26 | 2011-12-15 | Exelixis Inc | Moduladores de c-met e métodos de uso |
| DK1675961T3 (da) | 2003-10-24 | 2009-02-23 | Oncalis Ag | Fremgangsmåde til identifikation og/eller validering af receptortyrosinkinaseinhibitorer |
| FR2871158A1 (fr) | 2004-06-04 | 2005-12-09 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| WO2006080450A1 (ja) | 2005-01-27 | 2006-08-03 | Kyowa Hakko Kogyo Co., Ltd. | Igf-1r阻害剤 |
| WO2006111035A1 (en) | 2005-04-21 | 2006-10-26 | Oncalis Ag | Method for the identification of possibly harmful receptor tyrosine kinase (rtk) mutations and of inhibitors or medication directed against rtk mutantstitle |
| EP1899323A2 (en) | 2005-05-16 | 2008-03-19 | AstraZeneca AB | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
| CN101237873A (zh) | 2005-08-09 | 2008-08-06 | 美因茨约翰内斯古滕贝格大学 | 用于治疗非小细胞肺癌的星形孢菌素衍生物 |
| JP2009520825A (ja) | 2005-12-20 | 2009-05-28 | 武田薬品工業株式会社 | グルコキナーゼ活性剤 |
| DE102006030479A1 (de) | 2006-07-01 | 2008-03-20 | Merck Patent Gmbh | Indazolderivate |
| HRP20140688T1 (hr) | 2006-07-07 | 2014-10-24 | Bristol-Myers Squibb Company | Inhibitori piroltriazin kinaze |
| US7790756B2 (en) | 2006-10-11 | 2010-09-07 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| US20110008347A1 (en) | 2006-12-01 | 2011-01-13 | Agency For Science ,Technology And Research | Cancer-related protein kinases |
| EP2311807B1 (en) | 2006-12-08 | 2015-11-11 | Novartis AG | Compounds and composition as protein kinase inhibitors |
| CN101541788A (zh) | 2006-12-11 | 2009-09-23 | Irm责任有限公司 | 作为激酶抑制剂的化合物和组合物 |
| EP2120932B1 (en) | 2006-12-20 | 2014-07-09 | Nerviano Medical Sciences S.r.l. | Indazole derivatives as kinase inhibitors for the treatment of cancer |
| EP2173338A1 (en) | 2007-07-06 | 2010-04-14 | OSI Pharmaceuticals, Inc. | Combination anti-cancer therapy |
| PH12013501594A1 (en) | 2007-07-20 | 2014-05-12 | Nerviano Medical Sciences Srl | Substituted indazole derivatives active as kinase inhibitors |
| BRPI0816064B8 (pt) | 2007-08-29 | 2021-05-25 | Methylgene Inc | composto inibidor da atividade de proteína tirosina quinase, seu uso, e composição farmacêutica |
| AR074052A1 (es) | 2008-10-22 | 2010-12-22 | Array Biopharma Inc | Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa |
| US20100278921A1 (en) * | 2009-04-30 | 2010-11-04 | Fischer Cristina M | Solid oral formulation of abt-263 |
| AR086913A1 (es) | 2011-06-14 | 2014-01-29 | Novartis Ag | 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas |
| CN102924479A (zh) | 2011-08-09 | 2013-02-13 | 山东鲁北药业有限公司 | 一种星孢菌素类衍生物的半合成方法 |
| JP2015508644A (ja) | 2012-02-08 | 2015-03-23 | インサイト ジェネティクス インコーポレイテッド | 癌の診断および治療のためのｒｏｓ１の融合体に関する方法および組成物 |
| HUE034118T2 (en) | 2012-03-06 | 2018-01-29 | Pfizer | Macrocyclic derivatives for the treatment of proliferative diseases |
| EP2855460B1 (en) | 2012-05-23 | 2017-11-08 | Nerviano Medical Sciences S.r.l. | Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
| CN104968334B (zh) | 2012-09-28 | 2018-09-14 | 翁科埃斯克斯有限公司 | 包含噻吩并三唑并二氮杂卓化合物的药物制剂 |
| WO2014093750A1 (en) | 2012-12-14 | 2014-06-19 | Glaxosmithkline Llc | Method of administration and treatment |
| EP2988729A1 (en) * | 2013-04-25 | 2016-03-02 | Sun Pharmaceutical Industries Limited | Pharmaceutical gastro-retentive solid oral dosage form of nilotinib |
| US10231965B2 (en) | 2014-02-20 | 2019-03-19 | Ignyta, Inc. | Molecules for administration to ROS1 mutant cancer cells |
| CA2949160C (en) | 2014-05-15 | 2023-03-21 | Array Biopharma Inc. | 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor |
| EP3154549A1 (en) | 2014-06-13 | 2017-04-19 | Oncoethix GmbH | Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds |
| EP3227276B1 (en) | 2014-12-02 | 2021-09-01 | Ignyta, Inc. | Combinations for the treatment of neuroblastoma |
| WO2016089853A1 (en) | 2014-12-03 | 2016-06-09 | Ignyta, Inc. | Multiplexed immunohistochemistry assays for diagnosis and treatment of cancer |
| JP6929231B2 (ja) | 2015-05-29 | 2021-09-01 | イグナイタ インコーポレイテッド | Ｒｔｋ突然変異細胞を有する患者を処置するための組成物及び方法 |
| WO2016196671A1 (en) | 2015-06-01 | 2016-12-08 | Loxo Oncology, Inc. | Methods of diagnosing and treating cancer |
| CN108697708A (zh) | 2015-10-26 | 2018-10-23 | 洛克索肿瘤学股份有限公司 | Trk抑制剂抗性癌症中的点突变以及与此相关的方法 |
| BR112018012255A2 (pt) | 2015-12-18 | 2018-12-04 | Ignyta Inc | método para tratar câncer |
| AU2018302170B2 (en) | 2017-07-19 | 2024-02-29 | Ignyta, Inc. | Pharmaceutical compositions comprising entrectinib |
| CN111225662B (zh) | 2017-10-17 | 2022-11-22 | 伊尼塔公司 | 药物组合物和剂型 |
-
2018
- 2018-07-18 AU AU2018302170A patent/AU2018302170B2/en active Active
- 2018-07-18 CN CN202511566061.9A patent/CN121401264A/zh active Pending
- 2018-07-18 CN CN201880047029.1A patent/CN110913842A/zh active Pending
- 2018-07-18 CA CA3069339A patent/CA3069339A1/en active Pending
- 2018-07-18 BR BR112020000793-5A patent/BR112020000793A2/pt active Search and Examination
- 2018-07-18 JP JP2020502346A patent/JP7203083B2/ja active Active
- 2018-07-18 KR KR1020207002728A patent/KR102718538B1/ko active Active
- 2018-07-18 EP EP18756313.5A patent/EP3654952A1/en active Pending
- 2018-07-18 IL IL271759A patent/IL271759B2/en unknown
- 2018-07-18 US US16/039,196 patent/US10398693B2/en active Active
- 2018-07-18 WO PCT/US2018/042756 patent/WO2019018570A1/en not_active Ceased
- 2018-07-19 TW TW107125013A patent/TWI785074B/zh active
-
2020
- 2020-01-17 US US16/746,644 patent/US11253515B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020527575A5 (https=) | ||
| TWI409064B (zh) | Pharmaceutical composition | |
| JP7096164B2 (ja) | ジアミン誘導体を含む口腔内崩壊錠 | |
| JP2021519288A5 (https=) | ||
| JP5390014B2 (ja) | 抗凝固剤の溶出改善方法 | |
| ES2605034T3 (es) | Composición farmacéutica con solubilidad mejorada | |
| JP5749247B2 (ja) | 経口用徐放性固形製剤 | |
| JP2015501808A5 (https=) | ||
| JPWO2013022059A1 (ja) | ジアミン誘導体含有医薬組成物 | |
| JP2016509990A (ja) | 非晶質トルバプタンを含有する経口投与懸濁剤 | |
| JP5714562B2 (ja) | 経口用徐放性固形製剤 | |
| US9907789B2 (en) | Sustained-release preparation | |
| JP7674080B2 (ja) | アビラテロン酢酸エステル含有製剤 | |
| JP5870023B2 (ja) | 経口用徐放性固形製剤 | |
| CN105407925A (zh) | 用于泡腾剂型的制造工艺 | |
| RU2401109C2 (ru) | Таблетированный препарат с замедленным высвобождением для вертиго | |
| CN104490835A (zh) | 一种阿齐沙坦酯片剂及其制备方法 | |
| CA2925960A1 (en) | Pharmaceutical composition comprising capecitabine and cyclophosphamide | |
| KR20180036579A (ko) | 도네페질 또는 그의 약학적으로 허용 가능한 염 및 메만틴 또는 그의 약학적으로 허용 가능한 염을 함유하는 치매 및 인지기능 장애 예방 또는 치료용 약학 조성물 및 이의 제조방법 | |
| JP2016029029A (ja) | 経口組成物 | |
| JP6112696B1 (ja) | ソリスロマイシンを含む錠剤 | |
| JP2010270112A (ja) | 溶出改善されたケトチフェン又はその塩を含有する固形製剤 | |
| KR101806004B1 (ko) | 칸데사르탄 및 암로디핀을 포함하는 약제학적 조성물 | |
| TW201946916A (zh) | 醫藥製劑 | |
| JP2019073488A (ja) | アプレピタントを有効成分とする医薬錠剤 |